258 related articles for article (PubMed ID: 8509529)
1. Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia.
Dorian P; Newman D; Berman N; Hardy J; Mitchell J
J Am Coll Cardiol; 1993 Jul; 22(1):106-13. PubMed ID: 8509529
[TBL] [Abstract][Full Text] [Related]
2. Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence.
Lee SD; Newman D; Ham M; Dorian P
J Am Coll Cardiol; 1997 Jan; 29(1):100-5. PubMed ID: 8996301
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of isoproterenol on sustained ventricular tachycardia before and during procainamide and quinidine antiarrhythmic drug therapy.
Markel ML; Miles WM; Luck JC; Klein LS; Prystowsky EN
Circulation; 1993 Mar; 87(3):783-92. PubMed ID: 8443899
[TBL] [Abstract][Full Text] [Related]
4. Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs.
Kienzle MG; Martins JB; Wendt DJ; Constantin L; Hopson R; McCue ML
Am J Cardiol; 1988 May; 61(13):1012-7. PubMed ID: 3129926
[TBL] [Abstract][Full Text] [Related]
5. Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: a double-blind, randomized parallel evaluation. Sotalol Multicenter Study Group.
Singh BN; Kehoe R; Woosley RL; Scheinman M; Quart B
Am Heart J; 1995 Jan; 129(1):87-97. PubMed ID: 7817931
[TBL] [Abstract][Full Text] [Related]
6. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans.
Sager PT; Nademanee K; Antimisiaris M; Pacifico A; Pruitt C; Godfrey R; Singh BN
Circulation; 1993 Sep; 88(3):1072-82. PubMed ID: 8353869
[TBL] [Abstract][Full Text] [Related]
7. A comparison of sotalol and procainamide in symptomatic ventricular tachycardia.
Jordaens LJ; Colardyn F; Clement DL
Cardiovasc Drugs Ther; 1989 Apr; 3(2):155-61. PubMed ID: 2487531
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy of d/l sotalol in patients with sustained ventricular tachycardia refractory to class I antiarrhythmic drugs.
Kühlkamp V; Mermi J; Mewis C; Braun U; Seipel L
Eur Heart J; 1995 Nov; 16(11):1625-31. PubMed ID: 8881857
[TBL] [Abstract][Full Text] [Related]
9. The response to procainamide during electrophysiologic study for sustained ventricular tachyarrhythmias predicts the response to other medications.
Waxman HL; Buxton AE; Sadowski LM; Josephson ME
Circulation; 1983 Jan; 67(1):30-7. PubMed ID: 6847803
[TBL] [Abstract][Full Text] [Related]
10. Prolongation of ventricular refractoriness by class Ia antiarrhythmic drugs in the prevention of ventricular tachycardia induction.
Kus T; Costi P; Dubuc M; Shenasa M
Am Heart J; 1990 Oct; 120(4):855-63. PubMed ID: 2220538
[TBL] [Abstract][Full Text] [Related]
11. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment.
Kühlkamp V; Mewis C; Mermi J; Bosch RF; Seipel L
J Am Coll Cardiol; 1999 Jan; 33(1):46-52. PubMed ID: 9935007
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease.
Kus T; Campa MA; Nadeau R; Dubuc M; Kaltenbrunner W; Shenasa M
Am Heart J; 1992 Jan; 123(1):82-9. PubMed ID: 1729853
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine.
Hohnloser SH; van de Loo A; Baedeker F
J Am Coll Cardiol; 1995 Oct; 26(4):852-8. PubMed ID: 7560608
[TBL] [Abstract][Full Text] [Related]
14. Drug-induced torsade de pointes.
Raehl CL; Patel AK; LeRoy M
Clin Pharm; 1985; 4(6):675-90. PubMed ID: 2416504
[TBL] [Abstract][Full Text] [Related]
15. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness.
Wang J; Bourne GW; Wang Z; Villemaire C; Talajic M; Nattel S
Circulation; 1993 Sep; 88(3):1030-44. PubMed ID: 8353865
[TBL] [Abstract][Full Text] [Related]
16. Sotalol: An important new antiarrhythmic.
Anderson JL; Prystowsky EN
Am Heart J; 1999 Mar; 137(3):388-409. PubMed ID: 10047618
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest.
Haverkamp W; Martinez-Rubio A; Hief C; Lammers A; Mühlenkamp S; Wichter T; Breithardt G; Borggrefe M
J Am Coll Cardiol; 1997 Aug; 30(2):487-95. PubMed ID: 9247523
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of sotalol for drug-refractory malignant ventricular arrhythmias.
Gonzalez R; Scheinman MM; Herre JM; Griffin JC; Sauve MJ; Sharkey H
J Am Coll Cardiol; 1988 Dec; 12(6):1568-72. PubMed ID: 3192854
[TBL] [Abstract][Full Text] [Related]
19. Procainamide, disopyramide and quinidine: discordant antiarrhythmic effects during crossover comparison in patients with inducible ventricular tachycardia.
Wyse DG; Mitchell LB; Duff HJ
J Am Coll Cardiol; 1987 Apr; 9(4):882-9. PubMed ID: 3558987
[TBL] [Abstract][Full Text] [Related]
20. Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram.
Steinbeck G; Bach P; Haberl R
J Am Coll Cardiol; 1986 Oct; 8(4):949-58. PubMed ID: 3760368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
